Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis Marie Robin,

Slides:

Advertisements

Similar presentations

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

Advertisements

GLCCI1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease Alix O'Meara, Wahid.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease Melanie N. Stauber,

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological.

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty,

Vikas Gupta, Jason Gotlib, Jerald P. Radich, Nicolaus M

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Clostridium difficile Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcome Lise Willems, Raphaël.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation Nicolaus Kröger, Victoria Panagiota, Anita.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis Nicolaus Kröger, Tatjana Zabelina,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Long-Term Immune Reconstitution and Infection Burden after Mismatched Hematopoietic Stem Cell Transplantation Sophie Servais, Etienne Lengline, Raphaël.

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network.

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous.

Biology of Blood and Marrow Transplantation

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang,

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation Imad Abboud, Raphaël Porcher,

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Statistical Considerations in Studies of Late Effects in HCT

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor Marie Robin, Raphaël Porcher,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Viral Respiratory Infections Diagnosed by Multiplex PCR after Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Incidence and Outcome Alice.

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment Aliénor Xhaard, Vanderson Rocha, Benjamin.

Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long- Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation.

HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

What is quality in a transplant program?

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Blood and Marrow Transplant Handbook

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation Francis Ayuk, Galina.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis Marie Robin, Raphael Porcher, Christine Wolschke, Flore Sicre de Fontbrune, Haefaa Alchalby, Maximilian Christopeit, Bruno Cassinat, Tatjana Zabelina, Régis Peffault de Latour, Francis Ayuk, Gérard Socié, Nicolaus Kröger Biology of Blood and Marrow Transplantation Volume 22, Issue 7, Pages 1206-1211 (July 2016) DOI: 10.1016/j.bbmt.2016.02.019 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 OS (A), PFS (B), and cumulative incidence of relapse (C) and NRM (D) in the 2 study groups. The black curves represent the FM conditioning regimen; the red curves, the FB regimen. The solid lines correspond to estimates in the weighted sample; the dashed lines, to estimates in the original (unweighted) sample. This Figure is available in colour online at www.bbmt.org. Biology of Blood and Marrow Transplantation 2016 22, 1206-1211DOI: (10.1016/j.bbmt.2016.02.019) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions